Boston Scientific Corporation

NYSE:BSX

Medical - Devices

Healthcare
$43.64 +1.00%

+$0.45 today

Market cap
$63.25B
Beta
0.56
P/E (TTM)
19.0
EPS (TTM)
$2.39
52W Low $44.44High $109.50

Volume 13.21M

Average 19.45M

BSX EBITDA Margin

EBITDA as a percentage of revenue.

Boston Scientific CorporationNYSE: BSX

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 27.8%

EBITDA Margin was 27.8% in Q2 FY2026, up 0.8 pp from a year earlier. On a trailing-twelve-month basis it was 27.6%, up 2.2 pp year over year. Over 3 fiscal years it widened by 3.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 21 analysts of 35.6% for the fiscal year ending Dec 2026, up from 25.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
27.8%-3.0 pp QoQ
Last fiscal yearDec 2025
25.4%+1.9 pp YoY
LTMJun 2026
27.6%+2.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.8 pp+7.5 pp+6.7 pp
1 year+1.9 pp+10.2 pp+8.3 pp
3 years+3.8 pp+9.1 pp+5.3 pp
5 years+9.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
25.4%
Year-over-year change
+1.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BSX compares with its peers on the latest reported figures

  • BSX's LTM Jun 2026 EBITDA Margin of 27.6% is the highest of the 11 companies compared; the peer median is 13.2%.
  • Its year-over-year change of +2.2 pp is the 4th highest of 11, against a peer median of -0.2 pp.
  • Over three fiscal years its change of +3.8 pp compares with a peer median of +2.7 pp.
BSX Competitors Peer median
EBITDA Margin for BSX and competitors
Company Period LTM level YoY 3-year change
BSXBoston Scientific CorporationLTM Jun 202627.6% +2.2 pp+3.8 pp
MDTMedtronic plcLTM Jul 202627.3% +0.0 pp-0.9 pp
EWEdwards Lifesciences CorporationLTM Jun 202624.3% -7.1 pp-12.4 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202621.2% -0.0 pp+6.2 pp
PENPenumbra, Inc.LTM Jun 202614.8% -0.4 pp+12.4 pp
LIVNLivaNova PLCLTM Sep 202614.0% +20.0 pp-12.4 pp
CNMDCONMED CorporationLTM Mar 202612.4% -6.5 pp+10.5 pp
ATRCAtriCure, Inc.LTM Jun 20266.6% +8.5 pp+12.0 pp
ANGOAngioDynamics, Inc.LTM Feb 2026-1.7% -1.9 pp-2.9 pp
TFXTeleflex IncorporatedLTM Jun 2026-6.1% -25.9 pp-11.0 pp
CVRXCVRx, Inc.LTM Mar 2026-77.8% +9.1 pp+98.8 pp
Peer median (excluding BSX) 13.2%-0.2 pp+2.7 pp

Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.89B12.68B14.24B16.75B20.07B
Cost of Revenue4.43B4.97B5.41B6.48B6.22B
Gross Profit7.46B7.71B8.83B10.27B13.85B
Gross Margin62.8%60.8%62.0%61.3%69.0%
Research & Development1.2B1.32B1.41B1.62B2.05B
Selling, General & Admin4.29B4.52B5.19B5.98B6.89B
Operating Expenses5.54B5.89B6.65B7.63B9.88B
Depreciation & Amortization1.09B1.14B1.2B1.27B1.37B
EBITDA2.52B2.74B3.45B3.94B5.1B
EBITDA Margin21.2%21.6%24.2%23.5%25.4%
Operating Income1.92B1.82B2.18B2.64B3.97B
Operating Margin16.2%14.4%15.3%15.7%19.8%
Interest Income4M10M22M107M0
Interest Expense349M464M272M387M349M
Other Income / Expenses(846M)(683M)(196M)(353M)(586M)
Income Before Tax1.08B1.14B1.99B2.28B3.39B
Pre-Tax Margin9.1%9.0%13.9%13.6%16.9%
Income Tax Expense36M443M393M436M493M
Net Income1.04B698M1.59B1.85B2.89B
Net Margin8.7%5.5%11.2%11.1%14.4%
EPS (Basic)0.690.451.081.261.96
EPS (Diluted)0.690.451.071.251.94
Weighted Avg Shares1.42B1.43B1.45B1.47B1.48B
Weighted Avg Shares (Diluted)1.43B1.44B1.46B1.49B1.49B

Boston Scientific Corporation

NYSE:BSX

Intrinsic Alpha fair value

Locked

Current Price

$43.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.